The SWOG National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base (RB) has established itself as an innovative, collaborative, and integral part of the NCI's publicly funded cooperative group enterprise. The overall mission of the SWOG NCORP RB is to rapidly design, activate and complete biologically-driven, scientifically important, and clinically meaningful studies in cancer prevention, control, and cancer care delivery, in adults, adolescents and young adults with or at risk for cancer, and to improve quality of life and quality of survivorship for those with malignancies. Over the last grant cycle, the SWOG NCORP RB exceeded expectations with regard to scientific productivity, rapid dissemination of results, inclusiveness, faculty and student training, administrative efficiency, novel and complex trial designs, and advancement of and incorporation of the patient voice into all aspects of our work. In particular, the SWOG NCORP RB opens high-impact trials and conducts and completes them efficiently. During the reporting period, we accrued a total of 11,470 patients, of which 9897 (86%) were placed onto SWOG-coordinated studies, and 1573 (14%) were SWOG sites enrolling onto non-SWOG studies. SWOG NCORP institutions provided 45% of the accrual (n=4451) to SWOG-coordinated studies. Our results are widely disseminated and have informed multiple practice symptom management and survivorship guidelines. We published results from a large number of studies conducted during the last two cycles (125 manuscripts; 58 abstracts), with 34% issued in journals with an impact factor > 10. Overall, 96 NCORP site members were represented as authors in 54 NCORP manuscripts and abstracts. Over the next grant cycle, we will continue to expand our administrative and data infrastructure, with initiatives addressing patient reported outcomes, a robust and modern data management and patient reported outcomes core, enhanced engagement with community investigators and non-traditional partners, augmented education and involvement of patient advocates, and new quality initiatives. We will expand our research efforts in healthcare disparities across all committees, and we will collaboratively design, conduct, and accrue to novel and practice changing studies, in order to reduce the burden of cancer

Public Health Relevance

The overall mission of the SWOG National Cancer Institute Community Oncology Research Program Research Base is to rapidly design, activate and complete biologically-driven, scientifically important, and clinically meaningful studies in cancer prevention, control and cancer care delivery in adults, adolescents and young adults with or at risk for cancer, and to improve quality of life and quality of survivorship for those with malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189974-07
Application #
10001445
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Greenlee, Heather; Lew, Danika L; Hershman, Dawn L et al. (2018) Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Obesity (Silver Spring) 26:1539-1549
Hershman, Dawn L; Unger, Joseph M; Greenlee, Heather et al. (2018) Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 320:167-176
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Hershman, Dawn L; Unger, Joseph M; Crew, Katherine D et al. (2018) Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst 110:669-676
Chavez-MacGregor, Mariana; Unger, Joseph M; Moseley, Anna et al. (2018) Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Cancer 124:1760-1769
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Hershman, Dawn L; Till, Cathee; Shen, Sherry et al. (2018) Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. J Clin Oncol 36:2710-2717
Unger, Joseph M; Vaidya, Riha; Gore, John L (2018) Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol :

Showing the most recent 10 out of 143 publications